T. Kosaka

Science · 2004–2007

A researcher in the Science corpus: 4 papers; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Whom T. Kosaka trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. William Pao

Who trusts T. Kosaka overall

  1. Adi F. Gazdar
  2. T. Mitsudomi

Papers from T. Kosaka's perspective

Ordered by how strongly the researchers T. Kosaka trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
  2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy (Science)
  3. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  4. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain (PLoS Medicine)
  5. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
  6. Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
  7. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification (Science)
  8. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. (New England Journal of Medicine)
  9. Targeted cancer therapy (Nature)
  10. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways (Science)

Their papers